JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Becton Dickinson and Co

Closed

SectorHealthcare

185.78 1.25

Overview

Share price change

24h

Current

Min

185.31

Max

185.87

Key metrics

By Trading Economics

Income

27M

330M

Sales

104M

5.3B

P/E

Sector Avg

33.913

38.156

EPS

3.35

Dividend yield

2.23

Profit margin

6.259

Employees

70,000

EBITDA

93M

546M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+8.32% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.23%

2.50%

Next Earnings

7 Aug 2025

Next Dividend date

30 Sept 2025

Next Ex Dividend date

8 Sept 2025

Market Stats

By TradingEconomics

Market Cap

-15B

50B

Previous open

184.53

Previous close

185.78

News Sentiment

By Acuity

16%

84%

20 / 375 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Becton Dickinson and Co Chart

Past performance is not a reliable indicator of future results.

Related News

14 Jul 2025, 14:26 UTC

Acquisitions, Mergers, Takeovers

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5 Billion Deal -- 2nd Update

14 Jul 2025, 11:08 UTC

Acquisitions, Mergers, Takeovers

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal -- Update

14 Jul 2025, 10:37 UTC

Acquisitions, Mergers, Takeovers

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal

1 May 2025, 11:18 UTC

Earnings

Becton 2Q Net Down, Warns of Tariff Hit on 2025 EPS

15 Jul 2025, 18:32 UTC

Acquisitions, Mergers, Takeovers

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

15 Jul 2025, 18:31 UTC

Acquisitions, Mergers, Takeovers

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

14 Jul 2025, 16:12 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

14 Jul 2025, 15:06 UTC

Acquisitions, Mergers, Takeovers

Waters Stock Is Falling on Deal to Combine With Becton Dickinson Unit -- Barrons.com

14 Jul 2025, 14:11 UTC

Acquisitions, Mergers, Takeovers

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5B Deal -- 2nd Update

14 Jul 2025, 10:53 UTC

Acquisitions, Mergers, Takeovers

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal -- Update

14 Jul 2025, 10:22 UTC

Acquisitions, Mergers, Takeovers

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal

14 Jul 2025, 10:22 UTC

Acquisitions, Mergers, Takeovers

Waters To Assume About $4 Billion Incremental Debt >WAT BDX

14 Jul 2025, 10:22 UTC

Acquisitions, Mergers, Takeovers

Becton Dickinson to Get $4 Billion Cash Distribution Prior to Closing >WAT BDX

14 Jul 2025, 10:21 UTC

Acquisitions, Mergers, Takeovers

Waters Holders to Own 60.8% of Combined Company, Becton Dickinson Holders to Own 39.2% >WAT BDX

14 Jul 2025, 10:20 UTC

Acquisitions, Mergers, Takeovers

Waters, Becton Dickinson: Combined Company to Have About $9 Billion Revenue, $3.3 Billion Adjusted Ebitda >WAT

14 Jul 2025, 10:19 UTC

Acquisitions, Mergers, Takeovers

Correct: Waters, Becton Dickinson See About $290 Million Revenue Synergies by Year Five >WAT BDX

14 Jul 2025, 10:19 UTC

Acquisitions, Mergers, Takeovers

Waters, Becton Dickinson See About $345 Million Annualized Ebitda Synergies by 2030 >WAT BDX

14 Jul 2025, 10:18 UTC

Acquisitions, Mergers, Takeovers

Waters, Becton Dickinson See About $290 Revenue Cost Synergies by Year Five >WAT BDX

14 Jul 2025, 10:18 UTC

Acquisitions, Mergers, Takeovers

Waters, Becton Dickinson See About $200 Million Cost Synergies by Year Three >WAT BDX

14 Jul 2025, 10:17 UTC

Acquisitions, Mergers, Takeovers

Waters: Becton Dickinson Deal Doubles Total Addressable Market to About $40 Billion >WAT

14 Jul 2025, 10:16 UTC

Acquisitions, Mergers, Takeovers

Waters, Becton Dickinson Deal Structured as Reverse Morris Trust >WAT BDX

14 Jul 2025, 10:16 UTC

Acquisitions, Mergers, Takeovers

Waters, Becton Dickinson Deal Valued at About $17.5 Billion >WAT BDX

14 Jul 2025, 10:15 UTC

Acquisitions, Mergers, Takeovers

Waters to Combine With Becton Dickinson's Biosciences & Diagnostic Solutions Business >WAT BDX

14 Jul 2025, 10:15 UTC

Acquisitions, Mergers, Takeovers

Waters and BD's Biosciences & Diagnostic Solutions Business to Combine

1 May 2025, 10:33 UTC

Earnings

Becton Dickinson Cuts FY25 Adj EPS View on Tariff Impact

1 May 2025, 10:33 UTC

Earnings

Becton Dickinson FY25 Adj EPS View Includes an Estimated Tariff Impact of Approximately 25c

1 May 2025, 10:32 UTC

Earnings

Becton Dickinson Sees FY25 Organic Rev Growth Guidance of 3.0% to 3.5% >BDX

1 May 2025, 10:32 UTC

Earnings

Becton Dickinson Narrows FY25 View To Rev $21.8B-$21.9B >BDX

1 May 2025, 10:31 UTC

Earnings

Becton Dickinson Intends To Invest $2.5 B in U.S. Manufacturing Capacity Over the Next 5 Years >BDX

1 May 2025, 10:31 UTC

Earnings

Becton Dickinson: Taking 'Decisive Mitigation Actions to Navigate the Current Macro Environment' >BDX

Peer Comparison

Price change

Becton Dickinson and Co Forecast

Price Target

By TipRanks

8.32% upside

12 Months Forecast

Average 200.73 USD  8.32%

High 255 USD

Low 172 USD

Based on 13 Wall Street analysts offering 12 month price targets forBecton Dickinson and Co - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

13 ratings

4

Buy

9

Hold

0

Sell

Technical Score

By Trading Central

167 / 206.99Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

20 / 375 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.